Form 4: Corvus Director Granted 30,000 Stock Options

Corvus Pharmaceuticals Director David Scott Moore was granted 30,000 stock options with an exercise price of $7.04, vesting over three years.

Summary

• David Scott Moore, a Director of Corvus Pharmaceuticals, Inc. (CRVS), was granted 30,000 stock options.
• The options have an exercise price of $7.04 per share.
• The grant date for these options is October 2, 2025.
• The options will vest in three equal annual installments, with one-third (1/3rd) vesting on each anniversary of the grant date, contingent on continued service.
• The options expire on October 2, 2035.
• Following this transaction, David Scott Moore beneficially owns 30,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of options to a director is generally a positive signal of alignment and retention, as it ties the director's financial interests to the company's long-term stock performance. It does not, however, reflect operational performance or new strategic developments.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The options have a 10-year expiration period, providing a substantial window for potential value realization if the company's stock price appreciates.
• Equity compensation is a standard method for retaining key personnel and directors.

Negatives

• The value of the options is contingent on the company's stock price exceeding the exercise price of $7.04, meaning there is no guaranteed value.
• The options do not provide immediate cash compensation to the director.
• Future exercise of these options could lead to dilution of existing shares.

Risks

• The value of the options is contingent on the company's stock price exceeding the exercise price of $7.04, meaning the options could expire worthless if the stock price does not perform.
• Vesting of the options is subject to David Scott Moore's continued service relationship with Corvus Pharmaceuticals, Inc.
• Potential future dilution of existing shareholder equity if the options are exercised.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future operational or financial performance, focusing solely on an insider's equity transaction.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, as well as across public companies generally, to incentivize long-term performance and align management interests with shareholder value creation. This type of compensation is a standard component of executive and director remuneration packages.

Comparison to Industry Standards

• The grant of 30,000 stock options to a director is within the typical range for non-executive director compensation in the biotechnology sector, particularly for companies of similar market capitalization to Corvus Pharmaceuticals.
• The structure of a multi-year vesting schedule (one-third annually over three years) and a 10-year option term is standard for equity incentive plans across publicly traded companies, including those in the biotech industry (e.g., comparable to practices seen at companies like Kura Oncology or Mirati Therapeutics for director grants).

Related Party Transactions

• The grant of stock options to David Scott Moore, a Director of Corvus Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: Potential future dilution if the options are exercised, but also potential alignment of the director's interests with long-term shareholder value creation.
• Director (David Scott Moore): Receives a significant equity incentive, contingent on company performance and continued service, enhancing personal wealth potential.

Next Steps

• Continued service by David Scott Moore to ensure the vesting of the granted options.
• Potential future exercise of options by David Scott Moore if the company's stock price appreciates above the $7.04 exercise price.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director, which is a standard compensation practice. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would significantly alter an investment thesis. Investors should 'hold' and consider this information in the broader context of the company's overall performance and market conditions.

Keywords

Corvus Pharmaceuticals, CRVS, Stock Options, Director Compensation, Equity Grant, Insider Transaction, Form 4, Beneficial Ownership